Updated Jul 16, 2026
Schenkein David P has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $1.93M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | DNLI | Denali Therapeutics Inc. | A — Grant or award | 6.4K | $0.00 | |
| 2024-11-13 | DNLI | Denali Therapeutics Inc. | S — Open-market sale [10b5-1] | 32.3K | $32.87 | $1.06M |
| 2024-11-13 | DNLI | Denali Therapeutics Inc. | S — Open-market sale [10b5-1] | 27.1K | $32.09 | $871K |
| 2024-11-13 | DNLI | Denali Therapeutics Inc. | M — Option exercise [10b5-1] | 47.2K | $18.00 | $849K |
Schenkein David P is a corporate insider — currently tracked as Director of Prime Medicine, Inc. (PRME). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($1.93M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Schenkein David P profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.